clinical trials – Vet Clin Path Journal http://vetclinpathjournal.org/ Sat, 16 Apr 2022 00:03:30 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://vetclinpathjournal.org/wp-content/uploads/2021/05/cropped-icon-32x32.png clinical trials – Vet Clin Path Journal http://vetclinpathjournal.org/ 32 32 CSU researchers find antimalarial drugs can fight lung disease https://vetclinpathjournal.org/csu-researchers-find-antimalarial-drugs-can-fight-lung-disease/ Fri, 04 Mar 2022 22:04:14 +0000 https://vetclinpathjournal.org/csu-researchers-find-antimalarial-drugs-can-fight-lung-disease/

A research team from Colorado State University has found that drugs used to treat malaria are also effective in treating a lung disease similar to tuberculosis.

Their findings were featured on the cover of the February 23 issue of Science Translational Medicineone of the best scientific journals in the country.

The study is a significant development in the fight against infections caused by nontuberculous mycobacteria, or NTM, which are now more common than tuberculosis in the United States and often attack people who have weakened immune systems or pre-existing conditions like the disease chronic obstructive pulmonary or cystic fibrosis.

“There are currently very few antibiotics available to treat NTM infections, and some patients do not respond to any treatment,” said Professor Mary Jackson of the CSU’s Department of Microbiology, Immunology and Pathology, one of the main authors. “The prospect that antimalarial drugs that have already been in advanced clinical trials could become part of the arsenal of drugs available to fight these infections could have an immediate impact in the clinic.”

The research, led by Jackson and lead author Juan Manuel Belardinelli, a researcher in the Department of Microbiology, Immunology, and Pathology at CSU, targeted a NTM known as Mycobacterium abscessus. Few drugs are effective against this mycobacterium, and those that tend to be toxic and cause bad side effects, Jackson said.

]]>
MD&M West 2022 on 3D printing, biomaterials, robotics, digital health https://vetclinpathjournal.org/mdm-west-2022-on-3d-printing-biomaterials-robotics-digital-health/ Thu, 03 Mar 2022 21:13:15 +0000 https://vetclinpathjournal.org/mdm-west-2022-on-3d-printing-biomaterials-robotics-digital-health/

Medical Design & Manufacturing (MD&M) West, the largest medtech event in North America and hosted annually by Informa Markets – Engineering, unveils its educational programming for Design. Engineer. To construct. Conference. Speakers include experts from Medtronic, NXT Biomedical, Canary Medical, Galen Robotics, Edward Life Sciences, Philips, Tech Coast Angels, Stryker, Ethicon Endo-Surgery, AtriCure and UCLA BioDesign. Additionally, four partners – MedtechWomen, the Association for the Advancement of Medical Instrumentation (AAMI), Chemical Angel Network (CAN), and the Society of Plastics Engineers – Medical Plastics Division – will discuss the latest in the development of medtech, medical plastics, quality, and regulatory products at the two-day 9-title conference.

Taking place at the Anaheim Convention Center from April 12-14, 2022, MD&M West is one of five co-located trademarks for the one-stop-shop event called “IME West”, which also includes WestPack, Automation Technology Expo (ATX) West, Design & Manufacturing (D&M) West and Plastec West.

Mike Guerra, CEO of California Life Sciences (CLS), said of the event, “Coming together at this event will help the medical device community connect through educational sessions and discover new business partnerships on the exhibition floor, which is critical to our industry’s mission advancement.As medical device technology evolves in the life sciences sector, in-person connection is essential to accelerate the adoption of new technologies and new work processes that will improve the delivery of patient care.We are proud to partner with MD&M West and look forward to supporting the upcoming event that will help drive the science industry forward. the life.

Adrienne Zepeda, Group Events Director, MD&M West, added, “Even amid unprecedented challenges, we continue to see vital new innovations and exciting partnerships emerge that are fueling the multi-hundred-billion dollar industry. We are so proud to announce our conference partners who are to take the stage and share valuable insights and equip our attendees with sought-after solutions to improve product speed to market, inject new materials and technologies into devices, strengthen relationships with industry and accelerate trade.

The selected content of the conference is described below:

Panel: Development of innovative medical devices for dynamic market segments

MedtechWomen (Tuesday April 12, 4:00 p.m.)

New ideas, new scientific discoveries and new manufacturing technologies are generating new products and changing the way these products are designed and developed. The COVID-19 pandemic has imposed intense challenges on design and engineering teams, tasking them with rapidly pivoting products while simultaneously reinventing teamwork via remote access. Meanwhile, the growth of connected and data-driven products is expanding the range of skills and resources needed to produce the average medical device. Join our panel of industry experts who will discuss the challenges and opportunities of building market-leading products through emerging and rapidly changing applications.

Speakers from Dyad Engineering, UserWise, Materna Medical, Beacon Launch Partners and Simplexity Product Development.

Keynote: The science of predictive healthcare and the role of nano-polymers and medical plastics.

MiniTec by SPE (Tuesday, April 12, 8:00 a.m.)

Predictive medicine has its roots in early warning systems and early detection by diagnosis. Prognostic devices are a new breed of diagnostic devices that not only detect and diagnose disease, but predict and in many ways prevent the onset of disease. Imagine a point-of-care device that can detect BNP, a cardiac marker produced by the heart in minute amounts before the onset of arrhythmia. Then the doctor can prevent the disease by modifying the patient’s lifestyle, diet, and exercise. Early forays into predictive medicine more than a decade ago have spawned a new generation of predictive methods and prognostic medical devices. ctDNA liquid biopsy techniques (which detect cancer at very early stages and can pinpoint the location of the tumor) and metabolomic biosensors (which prevent strokes through a combination of bioelectronics, data science and IA) to tumor-hunting nanobots and scissor-based CRISPR (which snuff out faulty genes before disease onset), these methodologies are making expert-level preventative care accessible to millions of people at risk. Even in the Covid-19 pandemic, medical-grade plastics have had a significant impact – the most exciting development is the use of medical nano-polymers formed into carriers that prevent the mRNA vaccine from being destroyed by the body’s own defenses before they can do their job! The driving force behind all of this is Medical Plastics.

Speaker from mFluiDx.

Debate: Maintaining a Validated State for Connected Medical Devices, SaMD and DTx in the Age of Chaotic Innovation

AAMI (Wednesday, April 13, 8:30 a.m. – 5:00 p.m.)

From AI/ML to smartphones to cloud computing and web services, MedTech faces a growing imperative to leverage these technologies to support essential functions of a regulated medical device. The medical device manufacturer that creates and operates these new technologies admirably emphasizes continuous improvement, but is often not compatible with traditional MedTech approaches to regulated change management. As engineers, regulators and scientists, we can no longer ignore this uncomfortable truth. Instead, we need to adapt to a new set of software architectural approaches, best practices, and systems thinking, taking a more modern approach to device security and what validated state means.

Speakers from Philips and Orthogonal.

Keynote: Innovation Requirements: More than Materials Science and Biomedical Engineering

Chemical Angel Network (Wednesday, April 13, 8:30 a.m. – 5:00 p.m.)

The three-legged stool of medical device innovation requires great technical ability, of course, but also a deep understanding of the associated medicine (anatomy, pathology, procedural knowledge, outcomes, standards of care, clinical trials) and innovation business (patents, fundraising, management, strategy). These elements will be highlighted as the story of the development of the TAVR is told; the twists and turns of technological challenges, patents, difficult fundraising, difficult regulators and difficult strategic choices. Join industry-leading innovator Stanton Rowe as he discusses:

  • How to think about customer needs when customers don’t know what they need

  • Barriers to innovation – some technical, some market related
  • If you know the customer you serve, decisions about strategy are so much easier

Speaker from NXT Biomedical

Diagnostic Product Development – From Concept to Market

Lishan Aklog, MD, President and CEO, PAVmed Inc. (Tuesday, April 12, 4:00 p.m.)

The healthcare system has been enhanced post-Covid with a newly formed and expansive market for diagnostic tests that meets the needs of patients, clinical staff and, most importantly, payers. Home diagnostics is here to stay, but taking an IVD product from concept development to market is fraught with many questions and challenges. Join industry expert Dr. Lishan Aklog as he shares both trials and successes and gives you ideas on how to avoid problem areas.

Register here to get a conference pass today and learn about the latest technologies and solutions available on the market from the best experts in the medical technology industry.

Follow IME West on social media and join the conversation. #IMEWest #DiscoverEngineerBuild

Informa Markets’ Engineering is the publisher of MD+DI.

]]>
Institute of Infectious Diseases of the Institute of Human Virology https://vetclinpathjournal.org/institute-of-infectious-diseases-of-the-institute-of-human-virology/ Thu, 03 Mar 2022 04:18:20 +0000 https://vetclinpathjournal.org/institute-of-infectious-diseases-of-the-institute-of-human-virology/

BALTIMORE, March 3, 2022—The University of Maryland School of Medicine Institute of Human Virologya Global Virus Network (GVN) Center of excellence, physician researchers played a collaborative role in the successful transplant last month of a genetically modified pig heart into a patient with end-stage heart disease by creating strategies for monitoring pathogens and developing an infection prevention strategy for this important, unprecedented medical advance.

“Complications from infectious diseases are always a concern in the field of organ transplantation, whether they are infections related to the recipient or the donor, which in this case remarkably happens to be a pig,” said Kapil Saharia, MD, MPH, Assistant Professor of Medicine at the Institute of Human Virology at the University of Maryland School of Medicine and Chief of the Solid Organ Transplant Infectious Diseases Service at the University of Maryland Medical Center. “We are excited to work synergistically on this one-of-a-kind transplant by innovating in laboratory tests and protocols that enable monitoring of potential infections derived from pig donors. »

To reduce the risk of infection, the donor pig was raised in a disease-free laboratory environment and screened for many known porcine pathogens before being brought to the laboratory. Although all pigs are known to have the endogenous porcine retrovirus, researchers had not detected any transmission to humans or non-human primates in previous studies.

Procedures that transfer tissues or organs from one type of animal to another are known as xenotransplantations. The Cardiac Xenotransplantation Program of UMSOM, led by Bartley Griffith, MD, Thomas E. and Alice Marie Hales Emeritus Professor of Transplant Surgery at UMSOM, and Muhammad M. Mohiuddin, MDProfessor of Surgery at UMSOM, has tapped into the world renowned Institute to preemptively minimize any possible risk of potential infection.

“The quality of support from IHV for our experimental surgery has been of great help to us,” said Dr. Griffith. “Our preoperative preparation and postoperative pathogen monitoring has been a significant pathway to discovery and treatment.

Dr Mohuiddin said: “Although the evidence is lacking, there is real concern about porcine pathogens causing disease in humans. We will continue to follow the patient carefully with the help of the IHV for zoonotic diseases.

Robert C. Gallo, MD, Homer & Martha Gudelsky Emeritus Professor of Medicine and Co-Founder and Director of the Institute of Human Virology at UMSOM, and Co-Founder and International Scientific Director of the GVN said: “Nearly four years ago, the xenotransplantation group came to see us at the Institute of Human Virology for our expertise, in particular related to human retroviruses which are not unlike that of pigs. Dr. Gallo is world famous for his discovery of the first human retroviruses.

Using what other researchers have published on the porcine retrovirus, researchers at the Institute of Human Virology have developed an in-house PCR test that will be used to screen the organ recipient for the virus. The test will be used to monitor the exposure of healthcare workers to this retrovirus over the coming months. The test will also be used for research animal studies needed to advance this procedure to possible clinical trials. These infectious disease doctors will also monitor the patient for any signs of another opportunistic infection due to taking immunosuppressants.

As a prerequisite for emergency clearance from the FDA, the team developed a hospital infection prevention plan for the University of Maryland Medical Center. The doctors who designed the program included Dr. Saharia, Anthony Harris, MD, MPH, professor of epidemiology and public health and division chief of health care outcomes research at the University of Maryland School of Medicine; Surbhi Leekha, MBBS, MPH, associate professor of epidemiology and public health at the University of Maryland School of Medicine and medical director of infection control and hospital epidemiology at the University of Maryland Medical Center; and Michelle Harris Williams, director of infection prevention at the University of Maryland Medical Center.

“Given that this xenotransplantation was performed as part of life-saving surgery, it was difficult to develop workflows to minimize risk to our healthcare providers and hospital staff, as well as other patients. “, said Dr. Saharia. “We have no precedent for xenotransplantation in a clinical setting, so we worked closely with our own infection control epidemiologists to develop a plan that was safe for everyone involved.”

The infection prevention plan used disposable equipment where possible and rigorous disinfection protocols. Additionally, healthcare facilities are instructed to use enhanced contact precautions when caring for the patient, which includes wearing gloves, gowns, and proper hand hygiene, as well as face masks and eye protection due to the ongoing COVID-19 pandemic. To further reduce risk, patient specimens are hand-delivered to the laboratory and handled in the same manner as other highly infectious agents.

“We are happy to be part of a team led by Drs. Mohiuddin and Griffith over the past few years. This is certainly a milestone in the history of organ transplantation,” said Shyam Kottilil, MBBS, PhD, Professor of Medicine, Director of the Division of Infectious Diseases in the Department of Medicine and Director of the Division of Clinical Care and Research at the Institute of Human Virology at the University of Maryland School of Medicine and Senior Scientific Advisor to the GVN. “We will continue to work hand-in-hand with the team to ensure safety and improve clinical outcomes for this patient and others in the future.”

Anthony Amoroso, MD, The Professor of Medicine, Associate Chief of Infectious Diseases and Head of Clinical Care Programs at the University of Maryland Medical School Institute of Human Virology, said, “It’s very exciting that we can work in collaboration to support a pioneering achievement. of Drs. Griffith and Muhammad bringing xenotransplantation into the clinical arena.

Dr. Gallo added, “I would like to congratulate my colleagues in the Department of Surgery, its manager, Dr. Christine Lau, and the other people who contributed to the success of this transplant. Also, in particular, I congratulate the team of our Institute of Drs. Saharia, Kottilil and Amoroso and their colleagues, for their unwavering commitment to supporting this important program and their continued contribution to this unprecedented infectious disease control and detection program, especially in the face of a challenging immunocompromised clinical environment.

About the Institute of Human Virology

Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland, and the University of Maryland Medical System, IHV is an institute of the College of Medicine in the University of Maryland and is home to some of the most recognized and globally recognized experts in all of virology. IHV combines the disciplines of basic research, epidemiology and clinical research in a concerted effort to accelerate the discovery of diagnostics and therapies for a wide variety of chronic and life-threatening viral and immune disorders, including HIV, the virus that causes AIDS. For more information, visit ihv.org and follow us on Twitter @IHVmaryland.

About University of Maryland Medical School

Now in its third century, the University of Maryland Medical School was incorporated in 1807 as the first public medical school in the United States. It continues today to be one of the world’s fastest growing leading biomedical research enterprises – with 46 academic departments, centers, institutes and programs, and a faculty of more than 3,000 physicians, scientists and allied health professionals, including members. of the National Academy of Medicine and the National Academy of Sciences, and a two-time distinguished recipient of the Albert E. Lasker Award in Medical Research. With an operating budget of over $1.2 billion, the School of Medicine works closely with the University of Maryland Medical Center and Medical System to provide intensive research, academic, and clinical care to nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments ranking highly among all medical schools in the nation for research funding. As one of seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents and fellows. The combined medical school and medical system (“University of Maryland Medicine”) has an annual budget of more than $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks 8th among public medical schools in terms of research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the last US News and World Report ranking of best medical schools, released in 2021, UM School of Medicine is ranked #9 among 92 public medical schools in the United States and among the top 15% (#27) of 192 public and private medical schools in the United States. The School of Medicine works locally, nationally and globally, with research and treatment facilities in 36 countries around the world. To visit medschool.umaryland.edu


]]>
American Cancer Society CEO issues call to action on genitourinary cancer disparities https://vetclinpathjournal.org/american-cancer-society-ceo-issues-call-to-action-on-genitourinary-cancer-disparities/ Sat, 19 Feb 2022 02:11:46 +0000 https://vetclinpathjournal.org/american-cancer-society-ceo-issues-call-to-action-on-genitourinary-cancer-disparities/

February 18, 2022

4 minute read


Source/Disclosures

Source:

Knudsen KE. A way forward, a call to action: Addressing trends and disparities in genitourinary cancers. Presented at: ASCO Genitourinary Cancer Symposium; February 17-19, 2022; San Francisco.


Disclosures: Knudsen does not report any relevant financial information.


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

SAN FRANCISCO — Tackling disparities in genitourinary cancers requires more research into changing risk factors and immediate actions aimed at prevention, Karen E. Knudsen, PhD, MBA, said at the ASCO Symposium on Genitourinary Cancers.

Knudsen – who last year became CEO of the American Cancer Society and its advocacy affiliate, American Cancer Society Cancer Action Network – used her keynote address at the symposium to highlight trends in incidence and genitourinary cancer mortality in the United States, as well as priorities for the field.

More than 3.5 million cancer deaths have been averted since 1991 following a “doubling of investment in cancer research,” Knudsen said.

“Still, we are not entirely satisfied,” she added. “We know, even as we celebrate this 32% reduction in cancer mortality, that progress has not benefited everyone. … We still have a lot of work to do.

Karen E. Knudsen, MBA, Ph.D.

Karen E. Knudsen

Known sources of racial disparities in cancer outcomes include lack of transportation, need for housing near cancer centers, lack of health and digital literacy, hesitancy to enroll in clinical trials and unconscious bias among providers and health systems.

“Let’s take those truths that we know exist and go beyond implementation strategies,” she said.

Genitourinary cancers, which account for more than 20% of new cancer cases each year, pose a significant problem, Knudsen said. Prostate and bladder cancers alone are responsible for 14.4% of all cancer deaths in men, she added.

Bladder cancer

Disparities in bladder cancer include four times higher incidence and three to four times higher mortality in men than in women. This pattern is distinct from lung cancer profiles, which show gender convergence, Knudsen said.

Meanwhile, death rates have steadily declined among black men while remaining higher among white men, again different from lung cancer trends.

“From research, we can ask ourselves in terms of risk factors, is there something we’re missing?” Knudsen said. “We also know that there is currently no screening method for people at average risk. We are also watching the development of tests for the early detection of several cancers, and we look forward to strong evidence that these tests actually show clinical benefit.

Strategies that could be implemented immediately include increased smoking cessation efforts, she said.

kidney cancer

The long-term increase in the incidence of kidney cancer — mostly from diagnoses at the localized stage — can be attributed in part to the incidental detection of asymptomatic tumors through increased medical imaging, Knudsen said.

“There is a slow but steady increase by gender [and] demographic, so different from what we’ve seen with bladder cancer,” she said. “We suggest that the call to action here, in fact, is prevention, because approximately half of kidney cancers that are reported now can be prevented by eliminating important risk factors for this disease. [These] include being overweight and smoking.

Kidney cancer mortality, which has been declining since the mid-1990s, has remained relatively stable among black men despite their higher incidence rate, while increasing among both men and women.

Research should seek to identify the basis for the discrepancy in incidence and mortality among black men and lower incidence among Asian/Pacific Islanders, as well as additional risk factors, Knudsen said.

She suggested promoting healthy lifestyles and prevention strategies as immediate steps that can be taken.

Prostate cancer

Prostate cancer incidence dropped significantly following US Preventive Services Task Force recommendation against screening; however, it remains 73% higher among black men than among white men. The reasons for this difference remain unknown, Knudsen said.

Testing rates among black men and white men in the United States are roughly equal but remarkably low, she said.

“Although they are fair, I don’t think we can celebrate a third of the men [undergoing] prostate cancer screening,” Knudsen said.

A slight increase in the incidence of localized stage and regional stage disease occurred after readjustment of screening guidelines, but the most dramatic change was seen in distant stage disease, which increased by 4 % to 6% per year since 2011.

“For us at the American Cancer Society, this is a call to arms,” ​​Knudsen said.

The steep declines in death rates in all groups since the mid-1990s are starting to flatten out, which may indicate testing saturation or a need for new therapeutic strategies, Knudsen said.

His calls to action included refining screening and stepping up the search for new therapeutic strategies.

A review of regional differences in prostate cancer incidence and mortality in the United States revealed striking variations that should be investigated, Knudsen said. For example, incidence and mortality rates appeared to be balanced in Florida, while California had the lowest incidence but the highest mortality. In the Carolinas, black men had significantly higher death rates than white men, while in New York and Texas, black men and white men had equal outcomes.

“We know part of that is access to care,” Knudsen said.

Knudsen suggested the adoption of evidence-based screening to reverse the diagnostic shift to more advanced disease. She also highlighted the need for efforts to address disparities in outcomes by region and demographic group, the underuse of germline testing in localized disease, and variations in clinical trial uptake.

Testicular cancer

The incidence of testicular cancer increased for all subgroups, but Knudsen described the increase in incidence and mortality among Hispanics as alarming.

“There’s a big call to action here too, to increase testing, to increase awareness and to really understand the risk factors,” she said.

Regional variations have been identified across the country. For example, Louisiana has balanced testicular cancer incidence and mortality rates, while Arizona has the lowest incidence and highest mortality.

Understanding the basis for these variations should be a research priority, Knudsen said. “But right now we can increase awareness and we can increase uptake of testing,” she said. “I will flag to you, as CEO of the American Cancer Society, now that we have come to this realization, we will be part of this solution in states that have this high incidence.”

The references:

]]> DaVita Clinical Research Study Reveals Effectiveness of Common COVID-19 Vaccines at Parity for Patients with Kidney Failure https://vetclinpathjournal.org/davita-clinical-research-study-reveals-effectiveness-of-common-covid-19-vaccines-at-parity-for-patients-with-kidney-failure/ Thu, 17 Feb 2022 11:04:00 +0000 https://vetclinpathjournal.org/davita-clinical-research-study-reveals-effectiveness-of-common-covid-19-vaccines-at-parity-for-patients-with-kidney-failure/

DENVER, February 17, 2022 /PRNewswire/ — Dialysis patients who received an adenovirus vector-based COVID-19 vaccine (Johnson & Johnson) had similar rates of breakthrough infection, hospitalization and mortality as dialysis patients who received a mRNA-based vaccine (Pfizer/BioNTech), according to a DaVita Clinical Research (DCR) study published online ahead of print by the Journal of the American Society of Nephrology.

“Vaccination remains the most effective way to prevent serious illness from COVID-19 for dialysis patients,” said Dr. steven brunelli, MCSE, Vice President of DCR. “Our observations provide assurance that adenovirus vector-based COVID-19 vaccination, such as that produced by Johnson & Johnson, is an effective clinical strategy to help protect these patients from COVID-19 and from hospitalization or associated mortality.

More than 500,000 people in the United States who have been diagnosed with end-stage renal disease (ESKD) are receiving life-saving dialysis care. Due to underlying health conditions that compromise their immune systems, these patients are at increased risk for COVID-19. While mRNA vaccines have been shown to be effective in dialysis patients, researchers have sought to understand the effectiveness of adenovirus vector-based vaccines, as patients may receive the Johnson & Johnson vaccine due to its availability or its personal choice.

To assess the effectiveness of the Johnson & Johnson vaccine in dialysis patients, the researchers matched patients who had received this vaccine with those who had received Pfizer/BioNTech. A total of 2,572 matched pairs were evaluated from February 27, 2021 at September 28, 2021. The study found no difference in COVID-19 infection rates among patients treated with the Johnson & Johnson vaccine compared to the Pfizer/BioNTech vaccine during the first six months after vaccination.

The study further demonstrates that both vaccines were equally effective in helping to reduce the risk of hospitalization and death in the event of a breakthrough infection.

Since the start of the COVID-19 pandemic, DCR has conducted several studies to better understand how the novel coronavirus behaves in medically vulnerable patients with ESKD. Related research efforts also include the first large study demonstrating clinical efficacy of COVID-19 mRNA vaccines in ESKD patients.

To view the study in full, visit online ahead of print by the Journal of the American Society of Nephrology. To learn more about DaVita Clinical Research, visit DaVitaClinicalResearch.com.

About DaVita Clinical Research
DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Inc., is the research arm of DaVita. DCR innovates through retrospective research aimed at improving clinical outcomes. DCR assists pharmaceutical and medical device companies in the design, recruitment and execution of clinical trials using its network of renal research sites. To learn more about DCR, visit DaVitaClinicalResearch.com.

About DaVita Inc.
DaVita (NYSE: DVA) is a comprehensive kidney care provider focused on transforming care to improve the quality of life for patients around the world. The company is one of the largest providers of kidney care services in the United States and has been a leader in clinical quality and innovation for more than 20 years. DaVita strives to help increase equitable access to care for patients at every step and stage of their kidney health journey, from slowing the progression of kidney disease to streamlining the transplant process, from acute hospital care to home dialysis. From December 31, 2021, DaVita has served 203,000 patients at 2,815 ambulatory dialysis centers in the United States. The company operated 339 additional outpatient dialysis centers in ten countries around the world. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care community to adopt an equitable, high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

Contact details
Media:
Megane Anthony
(636) 675-6705
[email protected]

SOURCE DaVita Clinical Research

]]>
Talk about regenerative medicine and potential drug for COVID-19 https://vetclinpathjournal.org/talk-about-regenerative-medicine-and-potential-drug-for-covid-19/ Mon, 07 Feb 2022 02:05:22 +0000 https://vetclinpathjournal.org/talk-about-regenerative-medicine-and-potential-drug-for-covid-19/

Cymbeline “Bem” Culiat, co-founder, president and chief scientific officer of NellOne Therapeutics Inc. in Knoxville and former molecular geneticist at Oak Ridge National Laboratory, will speak virtually to Friends of ORNL at noon on Tuesday, February 8.

She will talk about “Future Applications in Regenerative Medicine” and part of her talk will be devoted to a potential treatment for people with severe COVID-19 and for “long haulers”, those people who have retained severe symptoms for a long time afterwards. have had the novel coronavirus.

While at ORNL, Culiat discovered the role of the signaling protein NELL1 in stimulating the growth and maturation of musculoskeletal and cardiovascular tissues in mice and other mammals, including humans. . His biotech company is focused on using his discovery to advance regenerative medicine, which involves replacing, engineering, or regenerating human or animal cells, tissues, or organs to promote healing and restore normal function. In contrast, traditional medicine generally provides treatment for the symptoms rather than addressing the root causes.